Artivion, Inc. (NYSE:AORT – Get Free Report) insider John E. Davis sold 15,100 shares of the business’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $23.61, for a total value of $356,511.00. Following the transaction, the insider now owns 208,778 shares in the company, valued at approximately $4,929,248.58. This represents a 6.74 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Artivion Stock Up 3.1 %
Shares of NYSE:AORT opened at $24.15 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88. Artivion, Inc. has a 52-week low of $19.11 and a 52-week high of $32.33. The firm has a market capitalization of $1.02 billion, a P/E ratio of -1,207.25 and a beta of 1.79. The stock has a 50 day moving average price of $28.66 and a 200-day moving average price of $27.72.
Artivion (NYSE:AORT – Get Free Report) last announced its quarterly earnings data on Monday, February 24th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of $0.12 by ($0.51). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The firm had revenue of $97.31 million for the quarter, compared to analysts’ expectations of $100.82 million. As a group, equities research analysts anticipate that Artivion, Inc. will post 0.37 EPS for the current fiscal year.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
AORT has been the subject of several research analyst reports. JMP Securities reiterated a “market outperform” rating and issued a $33.00 price objective on shares of Artivion in a report on Tuesday, December 10th. Stifel Nicolaus cut their price target on shares of Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a report on Tuesday, February 25th. Finally, Needham & Company LLC reduced their price objective on shares of Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday, February 25th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $31.40.
Get Our Latest Stock Report on AORT
About Artivion
Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.
Further Reading
- Five stocks we like better than Artivion
- Insider Trading – What You Need to Know
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- 3 Grocery Stocks That Are Proving They Are Still Essential
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- What is a penny stock? A comprehensive guide
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.